Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 4/20 | 0.75 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.75 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.75 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.75 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.75 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.75 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.65 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.65 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.65 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | DRD4 | P21917 | 2/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10251883 | 0.91 | CXCR4 (0.74) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL2073964 | 0.87 | PRKAA2 (0.78) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL1367196 | 0.86 | DRD4 (0.67) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL519372 | 0.86 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL7218186 | 0.85 | DRD4 (0.86) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL1366727 | 0.85 | CARM1 (0.58) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL694949 | 0.85 | SIGMAR1 (0.82) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL1367494 | 0.85 | SLC6A12 (0.62) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL1366388 | 0.84 | POLB (0.63) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL10248277 | 0.84 | PRKAA2 (0.54) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440417-B2 | Method for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440417-B2 | Method for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090286261-A1 | METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | CAYMAN CHEMICAL COMPANY (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286261-A1 | METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | CAYMAN CHEMICAL COMPANY (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009140364-A2 | METHODS FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | CAYMAN CHEMICAL COMPANY (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | PRKAA2 3883/4885PRKAB2 4386/4885PRKAG1 4286/4885 |
| US-20090286261-A1 | METHOD FOR ASSAYING COMPOUNDS OR AGENTS FOR ABILITY TO DISPLACE POTENT LIGANDS OF HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, HPGD, GMDS | PRKAA2 1240/4885PRKAB2 2202/4885PRKAG1 1170/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | PRKAA2 3883/4885PRKAB2 4386/4885PRKAG1 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.